JP2018048157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018048157A5 JP2018048157A5 JP2017195815A JP2017195815A JP2018048157A5 JP 2018048157 A5 JP2018048157 A5 JP 2018048157A5 JP 2017195815 A JP2017195815 A JP 2017195815A JP 2017195815 A JP2017195815 A JP 2017195815A JP 2018048157 A5 JP2018048157 A5 JP 2018048157A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nle
- polypeptide
- amide
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 150000001408 amides Chemical class 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 2
- 239000003087 receptor blocking agent Substances 0.000 claims 2
- 108091008803 APLNR Proteins 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 1
- 206010059027 Brugada syndrome Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims 1
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010016807 Fluid retention Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 102000003743 Relaxin Human genes 0.000 claims 1
- 108090000103 Relaxin Proteins 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 230000008484 agonism Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims 1
- 229960001267 nesiritide Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940117803 phenethylamine Drugs 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 206010047302 ventricular tachycardia Diseases 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591557P | 2012-01-27 | 2012-01-27 | |
| US61/591,557 | 2012-01-27 | ||
| US201261717760P | 2012-10-24 | 2012-10-24 | |
| US61/717,760 | 2012-10-24 | ||
| US201261731697P | 2012-11-30 | 2012-11-30 | |
| US61/731,697 | 2012-11-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553847A Division JP6313222B2 (ja) | 2012-01-27 | 2013-01-25 | 心不全治療用の合成アペリン模倣物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018048157A JP2018048157A (ja) | 2018-03-29 |
| JP2018048157A5 true JP2018048157A5 (enExample) | 2018-05-31 |
| JP6595553B2 JP6595553B2 (ja) | 2019-10-23 |
Family
ID=47997598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553847A Expired - Fee Related JP6313222B2 (ja) | 2012-01-27 | 2013-01-25 | 心不全治療用の合成アペリン模倣物 |
| JP2017195815A Expired - Fee Related JP6595553B2 (ja) | 2012-01-27 | 2017-10-06 | 心不全治療用の合成アペリン模倣物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553847A Expired - Fee Related JP6313222B2 (ja) | 2012-01-27 | 2013-01-25 | 心不全治療用の合成アペリン模倣物 |
Country Status (42)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8673848B2 (en) * | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
| US8921307B2 (en) * | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
| UY35144A (es) * | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| AU2013350802B2 (en) | 2012-11-30 | 2016-07-14 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
| EP3907237A1 (en) * | 2012-12-20 | 2021-11-10 | Amgen Inc. | Apj receptor agonists and uses thereof |
| EA201591700A1 (ru) * | 2013-03-14 | 2015-12-30 | Ридженерон Фармасьютикалз, Инк. | Гибридные белки апелина и их применение |
| EP3024847A1 (en) * | 2013-07-25 | 2016-06-01 | Novartis AG | Disulfide cyclic polypeptides for the treatment of heart failure |
| WO2015013169A2 (en) * | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
| WO2015013165A1 (en) * | 2013-07-25 | 2015-01-29 | Novartis Ag | Cyclic apelin derivatives for the treatment of heart failure |
| EP3024845A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic polypeptides for the treatment of heart failure |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| CA2931299C (en) | 2013-11-20 | 2024-03-05 | Regeneron Pharmaceuticals, Inc. | Aplnr modulators and uses thereof |
| ES2729643T3 (es) * | 2013-11-26 | 2019-11-05 | Novartis Ag | Métodos para la conjugación de oxima con polipéptidos modificados con cetona |
| WO2015089137A1 (en) | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
| DK3122764T3 (en) * | 2014-03-25 | 2019-04-15 | Lanthiopep Bv | CYCLIC APELINE ANALOGS |
| GB201407532D0 (en) | 2014-04-29 | 2014-06-11 | Univ Ulster | Apelin analogues |
| JP6721572B2 (ja) | 2014-05-23 | 2020-07-15 | ノバルティス アーゲー | ジスルフィド含有タンパク質からコンジュゲートを作製するための方法 |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| CN106573955B (zh) | 2014-06-23 | 2021-02-26 | 诺华股份有限公司 | 位点特异性蛋白质修饰 |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| SG11201704758XA (en) | 2015-01-23 | 2017-08-30 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
| EP3273981B1 (en) * | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of diabetes |
| MA42145B1 (fr) | 2015-05-20 | 2020-05-29 | Amgen Inc | Triazoles agonistes du récepteur apj |
| WO2017140684A2 (en) | 2016-02-15 | 2017-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction |
| EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| CN110072531A (zh) | 2016-10-19 | 2019-07-30 | 阿维夫公司 | 用于治疗心血管相关疾病的爱帕琳的新型聚乙二醇化的脂质体制剂 |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| EP3541802B1 (en) | 2016-11-16 | 2025-01-01 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
| WO2018093577A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| WO2019089335A1 (en) | 2017-11-03 | 2019-05-09 | Amgen Inc. | Fused triazole agonists of the apj receptor |
| EP3788037A1 (en) | 2018-05-01 | 2021-03-10 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| US12269847B2 (en) | 2018-08-16 | 2025-04-08 | Donaldson Company, Inc. | Genetically encoded polypeptide for affinity capture and purification of biologics |
| KR20210102887A (ko) | 2018-11-14 | 2021-08-20 | 알타반트 사이언시스 게엠베하 | 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제 |
| EP4107268A4 (en) | 2020-02-19 | 2024-03-27 | Donaldson Company, Inc. | PURIFICATION MATRICES COMPRISING VAA-BINDING POLYPEPTIDES AND METHODS OF USE THEREOF |
| US12692483B2 (en) | 2020-02-19 | 2026-07-28 | Donaldson Company, Inc. | Protein-based purification matrices and methods of using the same |
| CN112007027B (zh) * | 2020-09-14 | 2022-07-15 | 长春金赛药业有限责任公司 | 含酯基芳香丙酰胺类化合物及其代谢产物在制备治疗心衰药物中的应用 |
| GB202016149D0 (en) * | 2020-10-12 | 2020-11-25 | Heptares Therapeutics Ltd | Cyclic apelin receptor agonists |
| CN119101143A (zh) * | 2023-05-31 | 2024-12-10 | 浙江大学 | 一种G蛋白偏向的apelin-13多肽突变体及应用 |
| WO2026007693A1 (zh) * | 2024-07-05 | 2026-01-08 | 浙江大学 | Apelin-13多肽突变体 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2118372T3 (es) | 1992-11-17 | 1998-09-16 | Icos Corp | Nuevos receptores siete transmembrana v28. |
| US6555339B1 (en) | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
| CN1283228A (zh) | 1997-12-24 | 2001-02-07 | 武田药品工业株式会社 | 多肽、其生产方法及应用 |
| AU5759399A (en) | 1998-09-25 | 2000-04-17 | Takeda Chemical Industries Ltd. | Peptide derivative |
| ATE440857T1 (de) | 1998-10-05 | 2009-09-15 | Takeda Pharmaceutical | Verfahren zum eliminieren von n-terminalem methionin |
| US7045532B2 (en) | 1999-04-30 | 2006-05-16 | Millennium Pharmaceuticals, Inc. | ACE-2 modulating compounds and methods of use thereof |
| US7635751B2 (en) | 2000-03-23 | 2009-12-22 | Takada Pharmaceutical Company Limited | Peptides having ligand activities on APJ that is an orphan G protein-coupled receptor, and use thereof |
| WO2001090123A2 (en) | 2000-05-23 | 2001-11-29 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the agtrl1 gene |
| JP3935487B2 (ja) | 2001-07-16 | 2007-06-20 | フーベルト・ケスター | 捕獲化合物、その収集物、ならびにプロテオームおよび複合組成物の分析方法 |
| WO2003063892A1 (en) | 2002-01-29 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Use of apelin |
| DE602004027798D1 (de) | 2003-03-12 | 2010-08-05 | Univ Arizona State | Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen |
| US20050152836A1 (en) | 2003-05-22 | 2005-07-14 | Euan Ashley | Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof |
| US7947280B2 (en) | 2003-05-22 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Apelin and uses thereof |
| EP1520861A1 (en) | 2003-09-11 | 2005-04-06 | Aventis Pharma Deutschland GmbH | Test system for the identification of APJ receptor ligands |
| WO2005106493A1 (en) | 2004-04-30 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj) |
| AU2005265164A1 (en) | 2004-06-17 | 2006-01-26 | Musc Foundation For Research Development | Non-natural amino acids |
| US20060045880A1 (en) | 2004-08-23 | 2006-03-02 | Krieg Paul A | Methods for modulating angiogenesis and apoptosis with apelin compositions |
| JP2008013436A (ja) | 2004-10-14 | 2008-01-24 | Kanazawa Univ | 血管形成促進剤 |
| US20110097710A1 (en) | 2004-10-26 | 2011-04-28 | Macrae Calum A | Methods for detecting atrial fibrillation and related conditions |
| WO2006076736A2 (en) | 2005-01-14 | 2006-07-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions |
| EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| US8673848B2 (en) * | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
| EP1876448A1 (en) | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones. |
| US7736346B2 (en) | 2005-10-18 | 2010-06-15 | Biocardia, Inc. | Bio-interventional therapeutic treatments for cardiovascular diseases |
| US20080031871A1 (en) | 2006-02-21 | 2008-02-07 | Allen Margaret L | Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene |
| US20090324610A1 (en) | 2006-04-25 | 2009-12-31 | Kyushu Univeristy, National University Corporation | Gene associated with arteriosclerotic disease, and use thereof |
| US20100286029A1 (en) | 2007-09-11 | 2010-11-11 | Dorian Bevec | Use of a peptide as a therapeutic agent |
| WO2009033819A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| US20110123534A1 (en) | 2007-12-12 | 2011-05-26 | Erasmus University Medical Center Rotterdam | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
| WO2009075566A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Biomarkers for cardiovascular disease |
| RU2011122482A (ru) | 2008-11-04 | 2012-12-20 | Энкер Терапьютикс, Инк. | Apj-рецепторы соединения |
| WO2010115874A1 (en) | 2009-04-07 | 2010-10-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment and the diagnosis ofpulmonary arterial hypertension |
| JP2013509874A (ja) | 2009-11-04 | 2013-03-21 | エラスムス ユニバーシティ メディカル センター ロッテルダム | 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法 |
| CA2797033C (en) | 2010-04-22 | 2021-10-19 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
| TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| RU2457216C1 (ru) | 2010-12-21 | 2012-07-27 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) | Додекапептиды, обладающие кардиопротекторными свойствами |
| CN104254540A (zh) | 2012-01-09 | 2014-12-31 | 安科治疗公司 | Apj受体化合物 |
| EP3024845A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Cyclic polypeptides for the treatment of heart failure |
| EP3024847A1 (en) | 2013-07-25 | 2016-06-01 | Novartis AG | Disulfide cyclic polypeptides for the treatment of heart failure |
| WO2015013165A1 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Cyclic apelin derivatives for the treatment of heart failure |
| WO2015013169A2 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
-
2013
- 2013-01-23 US US13/747,621 patent/US8673848B2/en not_active Expired - Fee Related
- 2013-01-24 JO JOP/2013/0027A patent/JO3380B1/ar active
- 2013-01-24 UY UY0001034593A patent/UY34593A/es not_active Application Discontinuation
- 2013-01-25 TW TW102103025A patent/TWI576356B/zh not_active IP Right Cessation
- 2013-01-25 MY MYPI2014002154A patent/MY172268A/en unknown
- 2013-01-25 HU HUE13711953A patent/HUE039137T2/hu unknown
- 2013-01-25 PT PT137119533T patent/PT2807183T/pt unknown
- 2013-01-25 DK DK13711953.3T patent/DK2807183T3/en active
- 2013-01-25 JP JP2014553847A patent/JP6313222B2/ja not_active Expired - Fee Related
- 2013-01-25 CN CN201380016261.6A patent/CN104220452B/zh not_active Expired - Fee Related
- 2013-01-25 WO PCT/IB2013/050666 patent/WO2013111110A2/en not_active Ceased
- 2013-01-25 RS RS20180546A patent/RS57200B1/sr unknown
- 2013-01-25 SI SI201330999T patent/SI2807183T1/en unknown
- 2013-01-25 CA CA2862240A patent/CA2862240A1/en active Pending
- 2013-01-25 KR KR1020197037887A patent/KR20200003229A/ko not_active Ceased
- 2013-01-25 SG SG11201404369PA patent/SG11201404369PA/en unknown
- 2013-01-25 AR ARP130100228A patent/AR089808A1/es unknown
- 2013-01-25 HR HRP20180806TT patent/HRP20180806T1/hr unknown
- 2013-01-25 BR BR112014018306A patent/BR112014018306A8/pt not_active IP Right Cessation
- 2013-01-25 AU AU2013213265A patent/AU2013213265C1/en not_active Ceased
- 2013-01-25 CU CUP2014000097A patent/CU24266B1/xx unknown
- 2013-01-25 PL PL13711953T patent/PL2807183T3/pl unknown
- 2013-01-25 EP EP13711953.3A patent/EP2807183B1/en active Active
- 2013-01-25 KR KR1020147023505A patent/KR102068370B1/ko not_active Expired - Fee Related
- 2013-01-25 TR TR2018/07309T patent/TR201807309T4/tr unknown
- 2013-01-25 UA UAA201408328A patent/UA116196C2/uk unknown
- 2013-01-25 PE PE2014001176A patent/PE20142194A1/es active IP Right Grant
- 2013-01-25 EA EA201491433A patent/EA027853B1/ru not_active IP Right Cessation
- 2013-01-25 LT LTEP13711953.3T patent/LT2807183T/lt unknown
- 2013-01-25 NZ NZ627772A patent/NZ627772A/en not_active IP Right Cessation
- 2013-01-25 AP AP2014007846A patent/AP2014007846A0/xx unknown
- 2013-01-25 ES ES13711953.3T patent/ES2670832T3/es active Active
- 2013-01-25 MX MX2014009085A patent/MX351569B/es active IP Right Grant
-
2014
- 2014-01-28 US US14/165,680 patent/US9067971B2/en active Active
- 2014-07-22 ZA ZA2014/05400A patent/ZA201405400B/en unknown
- 2014-07-23 TN TNP2014000318A patent/TN2014000318A1/fr unknown
- 2014-07-24 IL IL233792A patent/IL233792B/en active IP Right Grant
- 2014-07-25 CL CL2014001994A patent/CL2014001994A1/es unknown
- 2014-07-25 GT GT201400166A patent/GT201400166A/es unknown
- 2014-07-25 PH PH12014501701A patent/PH12014501701A1/en unknown
- 2014-07-28 CR CR20140364A patent/CR20140364A/es unknown
- 2014-07-31 CO CO14167109A patent/CO7020879A2/es unknown
- 2014-08-27 EC ECIEPI201416014A patent/ECSP14016014A/es unknown
-
2015
- 2015-05-18 US US14/714,914 patent/US9982017B2/en not_active Expired - Fee Related
-
2017
- 2017-10-06 JP JP2017195815A patent/JP6595553B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-24 CY CY20181100556T patent/CY1120239T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016531110A5 (enExample) | ||
| JP2015506370A5 (enExample) | ||
| JP2016532681A5 (enExample) | ||
| WO2013111110A3 (en) | Synthetic apelin mimetics for the treatment of heart failure | |
| MX2016001021A (es) | Bioconjugados de polipeptidos de apelina sinteticos. | |
| Osadchii | Emerging role of neurotensin in regulation of the cardiovascular system | |
| Fu et al. | Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure | |
| JP2016501851A5 (enExample) | ||
| PH12016500104A1 (en) | Cyclic polypeptides for the treatment of heart failure | |
| AR093559A1 (es) | Mimeticos lineales sinteticos de apelina para el tratamiento de insuficiencia cardiaca | |
| JP2018507187A5 (enExample) | ||
| US20070244041A1 (en) | Peptide Yy Analogues | |
| WO2009053339A3 (en) | Cholesterol derivatives of inhibitors of viral fusion | |
| NZ591601A (en) | Therapeutic compositions containing macitentan and a prostacyclin receptor agonist | |
| JPWO2015141819A1 (ja) | 長時間作用型アドレノメデュリン誘導体 | |
| JP7001285B2 (ja) | 長時間作用型アドレノメデュリン誘導体 | |
| JP2016506914A5 (enExample) | ||
| JP2009545595A5 (enExample) | ||
| MX2017009534A (es) | Conjugados de acidos grasos y apelina sintetica con mayor vida media. | |
| JP2008505852A5 (enExample) | ||
| MANCIA et al. | Clinical advantages of lipophilic dihydropyridines | |
| Ahmad | Renin–angiotensin system blockade in diabetic nephropathy | |
| MA38866A2 (fr) | Bioconjugués de polypeptides d'apeline synthétiques | |
| AR096981A1 (es) | Bioconjugados de polipéptidos de apelina sintética | |
| Martynov et al. | Perindopril is angiotensin-converting enzyme inhibitor in treatment patients with arterial hypertension |